Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 10, 2007, Pages 1447-1454

  Langers, P ^a   Cremers, S C L M ^b   Den Hartigh, J ^a   Rijnbeek, E M T ^a   Ringers, J ^a   Lamers, C B H W ^a   Hommes, D W ^a   Van Hoek, B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MICROEMULSION; PRIORITY JOURNAL;

ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, CHEMICAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 35748956815     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03514.x     Document Type: Article

References (17)

1. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. Bio Drugs 2001 15 : 279 90.
2. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002 73 : S3 11.
3. Morton JM, Aboyoun CL, Malouf MA, Plit ML, Glanville AR. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 2004 23 : 1035 9.
4. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation 2002 73 : S19 22.
5. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998 66 : 1621 7.
6. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999 67 : 1133 7.
7. Lake JR. Benefits of cyclosporine microemulsion (Neoral) C(2) monitoring are sustained at 1 year in de novo liver transplant recipients. Transplant Proc 2001 33 : 3092 3.
8. Dunn S, Falkenstein K, Cooney G. Neoral C(2) monitoring in pediatric liver transplant recipients. Transplant Proc 2001 33 : 3094 5.
9. Barakat O, Peaston R, Rai R, Talbot D, Manas D. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients. Transplant Proc 2002 34 : 1535 7.
10. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002 73 : 953 9.
11. Langers P, Cremers SC, den Hartigh J, et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transpl 2004 10 : 183 9.
12. Langers P, Cremers SC, den Hartigh J, et al. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation. Aliment Pharmacol Ther 2005 21 : 549 57.
13. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther 1995 33 : 531 6.
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 9 : 503 12.
15. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004 2 (Suppl. 420S 5S.
16. Marin JG, Levine M, Ensom MH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006 28 : 637 42.
17. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001 23 : 100 14.